1. Home
  2. Live Updates
  3. Nash

Live Breaking News & Updates on Nash

Stay informed with the latest breaking news from Nash on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Nash and stay connected to the pulse of your community

HU6 Reduces Liver Fat, Body Weight in Patients with NAFLD with High BMI

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

Houston , Texas , United-states , Minnesota , Mazen-noureddin , Shaharyar-khan , Gastroenterol-hepatol , Houston-research-institute , Rivus-pharmaceuticals-to-present , Rivus-pharmaceuticals , Houston-methodist , Chief-scientific-officer

Patients with NASH, T2D Face Costly Financial Burden

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Veradigm-machaon-bonafede , Machaon-bonafede , Veradigm-network-integrated-dataset , Veradigm-life-sciences , Veradigm-network-integrated , T2d , Type-2-diabetes , Nafld , Nonalcoholic-fatty-liver-disease , Nash , Nonalcoholic-steatohepatitis , Healthcare

NASH treatments: Advanced drug candidates : Get Quote, RFQ, Price or Buy

Nonalcoholic steatohepatitis (NASH) is a massive public health challenge; Sino Biological is currently producing a huge range of NASH related drug targets and reagents.

United-states , American , Chuchu-qiao , Yun-kyoung-lee , Wanjun-guo , Sino-biological-inc , American-liver-foundation , Fatty-acid-synthase , Thyroid-hormone-receptor-beta , Peroxisome-proliferator-activated-receptor-alpha , Sino-biological , Lipid-metabolism

Sacked Cabinet minister Stuart Nash's new corporate gig revealed

Former Labour minister Stuart Nash has a new gig at a global recruitment firm.

New-zealand , Australia , Wellington , New-zealand-general- , Australian , Chris-hipkins , Mark-hutchinson , Newstalk-zb-mike-hosking , Mike-hosking , Shay-peters , Robert-walters , Stuart-nash

NC GOP leaders drop gambling expansion plans, pivot to include Medicaid coverage in budget

North Carolina Republican legislative leaders ditched late Tuesday efforts this year to dramatically multiply legal gambling in the state.

North-carolina , United-states , Hannah-schoenbaum , Phil-berger , Tim-moore , Roy-cooper , Associated-press , House-speaker-tim-moore , Senate-president-pro-tempore-phil-berger , Democratic-governor-roy-cooper , House-bill , Healthcare-options

Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis

1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with pegozafermin led to increased rates of NASH resolution. Evidence Rating Level: 1 (Excellent) Study Rundown: NASH is a disease characterized by hepatic inflammation and excess fat accumulation with or without fibrosis of the liver. Pegozafermin

Minute-medicine-inc , Rating-level , Controlled-trial , Confidence-interval , Chronic-disease , Fibrosis , Gastroenterology , Hepatology , Hypertriglyceridemia , Nash , Nonalcoholic-steatohepatitis-outcomes

3 Agents to Watch for Decompensated Cirrhosis from NASH

HepaStem, BIV201, and Albutein are late-stage pipeline agents in development for NASH, focusing specifically on decompensated cirrhosis.

United-states , America , John-tchelingerian , Sravani-meka , Sandra-camprubi , Promethera-group , Acute-on-chronic-liver-failure , End-stage-liver-disease , North-america , Announces-initiation , Biovie-announces , Patient-enrollment

Noninvasive ABDA Score Predicts Fibrotic NASH

Investigators developed the identification model based on significantly associated factors of fibrotic NASH and tested it in derivation and validation cohorts, where it identified 89.9% and 81.0% of patients with fibrotic NASH, respectively.

India , Shalimar , West-bengal , Nikhil-tandon , Centre-for-cardiac-risk-reduction , Indian-council-of-medical-research , India-institute-of-medical-sciences , Nash-education-program , Indian-primary-health-care-support-initiative , All-india-institute , Medical-sciences , North-india

Biden seen as sidelining rights issues on visits to India, Vietnam

US president’s travels disappoint rights advocates

Vietnam , Republic-of , White-house , District-of-columbia , United-states , Hanoi , Han-i , Washington , India , China , Narendra-modi , Joe-biden

Biomarker Panels Meet Criteria for Diagnostic Enrichment Qualification in Stage 1 of NIMBLE Project

Performance metrics of NIS4, the ELF test, and FibroMeter VCTE met prespecified criteria for qualification for regulatory approval in stage 1 of the NIMBLE project's circulating biomarker workstream.

Arun-sanyal , Virginia-commonwealth-university , National-institute-of-diabetes , Clinical-research-network , Virginia-commonwealth-university-arun-sanyal , Non-invasive-biomarkers , Metabolic-liver-disease , Research-network , National-institute , Kidney-diseases , Virginia-commonwealth